Human Longevity

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Solius is a company that manufactures a light therapy kiosk designed to stimulate the body's natural production of vitamin D through the use of specific wavelengths of ultraviolet B (UVB) light. Founded in 2011 and based in Bainbridge Island, Washington, Solius aims to address vitamin D deficiency by providing the benefits of sunlight without the harmful effects of UVA rays or the drawbacks associated with dietary supplements. The device enhances physical, mental, and immune function by promoting the production of essential hormones and peptides critical to overall health. Additionally, Solius has developed an ultraviolet light system intended for treating COVID-19. The company's focus on user experience and safety positions it as a pioneer in the medical device sector.

DoctorsForMe, established in 2018 and headquartered in South San Francisco, specializes in AI-driven healthcare solutions. The company connects patients with complex medical conditions to doctors who best match their specific needs, using a vast analysis of global data points to assess doctors' expertise and clinical excellence.

Celularity is a clinical-stage biotechnology company focused on advancing cellular medicine through the development of off-the-shelf placental-derived allogeneic cell therapies. Its product pipeline includes unmodified and genetically modified natural killer (NK) cells, CAR-engineered T cells, and mesenchymal-like adherent stromal cells. The company targets various health conditions, including cancer, immunologic disorders, infectious diseases, and degenerative illnesses. Celularity leverages the unique biology of the placenta, aiming to create effective and accessible therapies to address significant unmet medical needs. In addition to its cell therapy initiatives, Celularity operates a bio-banking segment, which contributes substantially to its revenue.

OxStem Limited, incorporated in 2011 and based in Oxford, United Kingdom, focuses on developing cell programming therapies aimed at treating degenerative diseases with significant unmet medical needs. The company intends to create small molecule drugs that activate the body's inherent repair mechanisms. By leveraging extensive experience in medicinal chemistry, OxStem aims to design innovative treatments that can program resident stem and stem-like cells in situ, targeting age-related conditions that are currently untreatable.

Cypher Genomics, Inc. is a genome informatics company that specializes in automated human genome interpretation software solutions targeted at clinical labs, pharmaceutical companies, and population genomics initiatives. Founded in 2011 and based in La Jolla, California, the company's platform enables clinical laboratories to adjust sensitivity and specificity profiles for developing molecular tests for diagnostic and prognostic purposes. Additionally, it assists pharmaceutical firms in identifying biomarkers from whole genome sequence data, particularly in early-stage drug development studies. Cypher Genomics offers solutions such as Mantis, a software-as-a-service that provides clinical-grade summaries for genomic analyses, and Coral, a biomarker discovery service that integrates genome sequencing with clinical data to aid in therapy development. The company has established strategic partnerships with notable organizations in the field, including Celgene and Illumina. Cypher Genomics is now a subsidiary of Human Longevity, Inc.